NCT03976102 - Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma | Biotech Hunter

Enrollment

317

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

September 28, 2022

Study Completion Date

February 27, 2023

Conditions

Follicular Lymphoma

Interventions

BIOLOGICAL

DRL_RI (Proposed rituximab biosimilar)

Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion

OTHER

MabThera®

Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion

Trial Locations (4)

American Oncology Partners of Maryland, Bethesda

University of Tennessee Medical Center - Cancer Institute, Knoxville

Gulf coast Oncology Associates, PA, Houston

The Oncology Institute of Hope and Innovation, Whittier